References
- Louis E, Collard A, Oger AF, Degroote E, Abdoul Nasr El Yafi F, Belaiche J. Behaviour of Crohn's disease according to the Vienna Classification: changing pattern over the course of the disease. Gut 2001; 49: 777–82
- Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244–50
- D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667–71
- Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment fort the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433–42
- D'Haens G, Hommes D, Baert F, Van Assche G, Caenepeel P, Vergauwe P, et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology 2006; 130(Suppl 2)A110
- Kandiel A, Fraser AG, Korelitz, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–5
- Colombel JF, Loftus EV, Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31
- Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650–6
- Silverberg M, Satsangi J, Ahmad T, Amott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A)5A–36A
- Jess T, Rijs L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481–9
- Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124–30
- Vernier-Massouille G, Baldé M, Gower-Rousseau C, Brazier F, Girard A, Merle V, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease: a population-based cohort study. Gastroenterology 2007; 132(Suppl 2)A16
- Prajapati DN, Saeian K, Kim JP, Kugathasan S, Knox J, Emmons J, et al. Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease. Gastroenterology 2002; 122: A100
- Louis E, Boverie J, Dewit O, Baert F, DeVos M, D'Haens G. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 15–19
- Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicenter study of 121 cases. Gut 1994; 35: 231–5
- Shah A, Morgan G, Rose JD, Fifield R, Rhodes J. Platelet number and size in relation to serum orosomucoid concentration in Crohn's disease. Med Lab Sci 1989; 46: 79–80
- Danese S, de Motte C L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938–5